Acyclic Nucleoside Phosphonates: a Key Class of Antiviral Drugs

Overview

Journal Nat Rev Drug Discov

Specialty Pharmacology

Date 2005 Nov 3

PMID 16264436

Citations 175

Authors

Erik De Clercq

Antonin Holy

Affiliations

Soon will be listed here.

Abstract

Almost 20 years after the broad antiviral activity spectrum of the first acyclic nucleoside phosphonates was described, several of these compounds have become important therapies for DNA virus and retrovirus infections. Here, we review the discovery and development of acyclic nucleoside phosphonates, focusing on cidofovir and its potential in the treatment of various herpes-, papilloma-, polyoma-, adeno- and pox-virus infections, adefovir for the treatment of hepatitis B and tenofovir for the treatment of AIDS and the prevention of HIV infections.

Citing Articles

Antiviral Agents: Structural Basis of Action and Rational Design.

Menendez-Arias L, Gago F Subcell Biochem. 2024; 105:745-784.

PMID: 39738962 DOI: 10.1007/978-3-031-65187-8_20.

Human cytomegalovirus: pathogenesis, prevention, and treatment.

Shang Z, Li X Mol Biomed. 2024; 5(1):61.

PMID: 39585514 PMC: 11589059. DOI: 10.1186/s43556-024-00226-7.

Nanoengineering of Phosphate/Phosphonate Drugs via Competitive Replacement with Metal-Phenolic Networks to Overcome Breast Tumor with Lung and Bone Metastasis.

Shi W, Liu D, Feng W, Chen Y, Wang Y, Nie Z Adv Sci (Weinh). 2024; 12(2):e2413201.

PMID: 39555815 PMC: 11727113. DOI: 10.1002/advs.202413201.

Building Metabolically Stable and Potent Anti-HIV Thioether-Lipid Analogues of Tenofovir Exalidex: A thorough Pharmacological Analysis.

DErasmo M, Sharma S, Pribut N, Basson A, Dasari M, Bartsch P J Med Chem. 2024; 67(20):18204-18220.

PMID: 39411803 PMC: 11513920. DOI: 10.1021/acs.jmedchem.4c01510.

New Therapies and Strategies to Curb HIV Infections with a Focus on Macrophages and Reservoirs.

Marra M, Catalano A, Sinicropi M, Ceramella J, Iacopetta D, Salpini R Viruses. 2024; 16(9).

PMID: 39339960 PMC: 11437459. DOI: 10.3390/v16091484.